Bristol On Track For Growth In 2007 Despite Pargluva Setback
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol is reallocating resources toward existing products and aiming to reach growth targets through other pipeline candidates following the delay and possible termination of muraglitazar.
You may also be interested in...
Bristol, Sanofi Pledge To Defend Plavix Patent In Face Of Potential “At Risk” Launch
FDA grants final approval to Apotex’ ANDA for the antithrombotic, fueling speculation over timing of generic entry.
Bristol, Sanofi Pledge To Defend Plavix Patent In Face Of Potential “At Risk” Launch
FDA grants final approval to Apotex’ ANDA for the antithrombotic, fueling speculation over timing of generic entry.
Bristol To Consider Sales Force Cuts Following Pargluva Delay
The setback in development of the diabetes agent also leads Bristol to announce a $500 mil. savings strategy for 2007.